AmnioGraft®: Treating Ocular Conditions Like Pterygium
The Gold Standard for Pterygium Surgery
The Gold Standard for Pterygium Surgery
Over the years of treating Pterygium patients, Neel Desai, MD developed an effective technique for primary pterygium surgery using AmnioGraft that reduced recurrence rate and surgical time with little to no pain reported.
Fill out the contact form and download the free surgical guide.
AmnioGraft, an amniotic membrane graft, helps rapidly restore the healthy ocular surface when used during ocular surface reconstruction surgery, especially with pterygium and conjunctivochalasis (CCh) procedures. Delivering the unique therapeutic advantage of cryopreserved amniotic membrane tissue, AmnioGraft can help your patients achieve superior cosmetic outcomes and maximize longterm results.3,4,6,7
Ophthalmologists need proven outcomes.
500K
TRANSPLANTS
360
CLINICAL PUBLICATIONS
30Y
RESEARCH & DEVELOPMENT
Why Intervene with AmnioGraft?
Why Intervene with AmnioGraft?
Discover AmnioGraft®
A transplantation graft used by ophthalmologists around the world to manage
ocular surface indications such as corneal ulcers, pterygium, Stevens-Johnson Syndrome, and conjunctivochalasis (CCh).
Support Accelerated Post-Op Recovery1
AmnioGraft® expedites patient recovery by reducing inflammation5,9-11 and promoting fast, regenerative healing – typically within 2-3 weeks1-7. It helps prevents disease recurrence 1,2,6-8 as demonstrated in a study of 535 patients. AmnioGraft creates a durable recurrence barrier proven to support sustained healing with ≤5.8%* recurrence after 1 year1.
Creating a Healing Environment
AmnioGraft contains the only cryopreserved amniotic membrane that is FDA-cleared and designated for anti-inflammation, anti-scarring and anti-angiogenesis. Proprietary CryoTek preservation method retains the biologic properties and structural integrity is equivalent to fresh tissue2,12.
See What Others Are Saying About AmnioGraft
See What Others Are Saying About AmnioGraft
Mark Milner, MD
“Dry eye disease isn’t just simply a problem with quantitative tear film, meaning a low tear volume. Dry eye can also be from an abnormal tear film where you have tears, but they’re either unhealthy, or they’re not getting to the location that they need to, and one of the classic examples is what we call ‘Conjunctivochalasis’ or Mechanical Dry Eye.”
Neel Desai, MD
“We’ve all had the paradoxical patient that seems to have dry eye and typical ocular surface disease, but they simply don’t respond to all of the typical conventional therapies…there is a missing x-factor. And that x-factor is this Mechanical Dry Eye concept, or conjunctivochalasis.”
Cliff Salanger, MD
“Mechanical Dry Eye is rampant; it’s almost ubiquitous in individuals over the Medicare age of 65, and we have to look for it. The key is making the diagnosis. I get fooled still. I look, white light shining the slit beam across, and I’m thinking to myself, ‘Oh, there’s not a whole lot of redundant conjunctiva here.’ I put the fluorescein in, I turn on the cobalt blue light, and then even better, I put a yellow filter on the other side of the microscope, and it highlights the redundant fold of the conjunctiva.”
DISCLAIMER
BioTissue, Inc. will use reasonable efforts to include accurate and up-to-date information on this Website but makes no warranties or representations of any kind as to its accuracy, currency, or completeness.
The contents of this web site are protected by applicable copyright laws. No permission is granted to copy, distribute, modify, post or frame any text, graphics, video, audio, software code, or user interface design or logos.
The information contained on this website is for general information and educational purposes only, and is not intended to diagnose, treat, or cure any medical conditions. Please consult with your Physician for medical advice.
BioTissue, Inc. and its affiliates furnish this allograft product without any express or implied warranties. All statements or descriptions are informational only and are not to be interpreted or implied as a warranty of the allograft product. BioTissue, Inc. and its affiliates make no guarantee regarding the biological characteristics of this product. The end user shall be held responsible for determining the appropriate application and usage of this product.